>
The Backdrop to America's Underbelly
Vitamin D deficiency fuels autoimmune conditions, dysregulating immune function
What If AI Isn't Intelligence, But Anti-Intelligence?
Fighting the Devil and Winning – Bas Rutten on Faith, Demons, and Discipline - SF611
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
AI Getting Better at Medical Diagnosis
Tesla Starting Integration of XAI Grok With Cars in Week or So
Bifacial Solar Panels: Everything You NEED to Know Before You Buy
INVASION of the TOXIC FOOD DYES:
Let's Test a Mr Robot Attack on the New Thunderbird for Mobile
Facial Recognition - Another Expanding Wolf in Sheep's Clothing Technology
Two adults with leukaemia have been in remission since 2010 after Car-T therapy.
It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body's immune system to attack tumours.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: "Based on these results, we can conclude that Car-T cells can cure leukaemia.
"These cells continued to demonstrate tumour-killing characteristics."
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: "I knew the doctors weren't sure but I was pretty convinced that I was done with cancer."
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.